Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer

NCT06921837 is registered in ClinicalTrials.gov with Bolt Biotherapeutics, Inc. as lead sponsor.

NCT NCT06921837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06921837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer
Lead sponsor
Bolt Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 26, 2025
Completion date
May 31, 2029
Enrollment
122 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer adenocarcinoma metastatic, gastroesophageal adenocarcinoma